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A commentary on 
Clinical Approach to the Differential Diagnosis between Behavioral Variant Frontotemporal 
Dementia and Primary Psychiatric Disorders
by Ducharme S, Price BH, Larvie M, Dougherty DD, Dickerson BC. Am J Psychiatry (2015) 
172(9):827–37. doi:10.1176/appi.ajp.2015.14101248
We welcome the recently published review by Ducharme and colleagues (1) and wish to highlight 
matters pertinent to aggressive behavior in their report. Aggression in psychiatric hospitals has 
gained widespread public attention (2). Mentally ill treatment-refractory patients who display 
aggressive behavior are either transferred to maximum-security forensic state hospitals (3) or sent 
to correctional facilities, which often struggle to keep up with the epidemic of mental illness and 
shortage of psychiatrists (4). Fourteen percent of patients with behavioral variant frontotemporal 
dementia (bvFTD) present initially to psychiatric care due to criminal behaviors (5). This highlights 
the importance of considering bvFTD as one of the key differential diagnosis in treatment-refractory 
forensic patients with progressively worsening cognitive functioning and high rates of violence as 
well as in patients with new-onset criminal behavior. Emerging biomarker-based reports indicate 
substantial overlap in cognitive dysfunction and underlying anatomical and functional brain abnor-
malities, such as frontotemporal gray matter loss, spanning psychotic disorders (6), and dementias 
(1). These findings call for novel dimensional approaches to psychiatric diagnoses and treatment 
such as those emphasized by the Research Domain Criteria (RDoC) initiative (7).
We have reported on our successful management of such a case from a maximum-security 
hospital, who presented with long history of psychosis refractory to multiple treatment interven-
tions including clozapine and electroconvulsive therapy (8). Our treatment decisions were driven by 
revision of diagnosis from schizoaffective disorder to FTD, based on cognition (Repeatable Battery 
for the Assessment of Neuropsychological Status and Montreal Cognitive Assessment) and neuroim-
aging (structural magnetic resonance imaging) workup, as well as by utilizing measurement-based 
care (MBC) (9). The principles of MBC include routine measurements of symptoms, side effect, 
and tolerability along with modification of treatment regime based on these measurements, while 
best defined for treatment of major depression can be extended to management of other chronic 
mental illnesses (9). We used data collected as part of state-law mandated monitoring of restraint(s) 
and/or seclusion(s) (10) to serve as measurements, which guided our decision to change medica-
tions or their dose. For example, during the course of treatment and as reported previously (8), 
we re-evaluated the utility of medroxyprogesterone by reducing its dose and frequency, which was 
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associated with sharp increase in aggression. Utilizing principles 
of MBC, we re-instated the dose of medroxyprogesterone and 
added sertraline, which in turn resulted in even greater reduction 
in aggression. As impulsivity and disinhibition are hypothesized 
to underlie the aggression in bvFTD patients, 37.4% of whom 
exhibit criminal behaviors (5), we implemented structured 
behavioral and environmental modification programs. These 
interventions led to considerable improvement in the patient’s 
psychosis, social behaviors, impulsivity, aggression, and insight, 
despite persistent cognitive symptoms.
This systematic review by Ducharme and colleagues is a 
valuable addition to literature offering a clear, step-wise differ-
ential diagnosis algorithm directly applicable to various clinical 
settings. However, lack of access to neuroimaging and expert 
consultation services in state hospitals and correctional facilities 
may hinder accurate diagnosis of bvFTD leading to under- or 
over-diagnosis, especially as its prevalence is 10–100 times lower 
than primary psychiatric disorders. This calls for system-level 
efforts, such as greater collaboration between academic centers 
and forensic mental health settings (4), as well as mechanistic 
research targeting pathophysiology and treatment developments 
of this devastating neurodegenerative syndrome.
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